Clinical trials: Acquired Immune Deficiency Syndrome Virus
TB - Tuberculosis, HIV/AIDS
Pre- and Post-treatment Lung Microbiota, Metabolome and Immune Signatures at the Site of Disease in Patients With Active Pulmonary Tuberculosis
The diverse microbial communities in different parts of the human body (microbiome) are important for health but understudied in pulmonary tuberculosis (TB), which is the single biggest infectious cause of death in the world.
- Trial name
- TB-LUNG (NCT04700579)
- Where
- 3 sites in South Africa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Stellenbosch
Kaposi Sarcoma, HIV/AIDS
Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
Infection with Kaposi sarcoma herpesvirus (KSHV, or human herpesvirus-8 (HHV-8)) causes Kaposi sarcoma (KS). These virally associated diseases occur more frequently in HIV-infected individuals, but can also be found in…
- Conditions
- Kaposi Sarcoma, HIV/AIDS, Immunosuppression
- Trial name
- NCT03316274
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Tobacco, Tobacco Abstinence
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH).
- Conditions
- Tobacco, Tobacco Abstinence, Smoking Cessation, Smoking Cessation; Tobacco Dependence
- Trial name
- QMH (NCT06883097)
- Testing
- Learn to Quit-HIV (LTQ-H) App, QuitStart
- Where
- United States
- Volunteers
- 314 people
- Sponsor
- Wake Forest University Health Sciences
Cytomegalovirus Retinitis, HIV Infections
A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir
To study the safety and effectiveness of foscarnet in the treatment of AIDS patients who have active infection with cytomegalovirus (CMV) that is causing inflammation of the retina (retinitis).
- Trial name
- NCT00000697
- Testing
- Foscarnet sodium
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus (HIV), AIDS Virus
Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults
This study will evaluate the safety and tolerability (including reactogenicity) of candidate vaccine A244/B.63521 with Army Liposome Formulation (ALF) mixed with the saponin QS-21(Quillaja saponaria-21) (ALFQ) adjuvant.
- Trial name
- RV575 (NCT05423418)
- Testing
- A244, B.63521, 50μg ALFQ
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV Infections, HIV-Associated Lipodystrophy Syndrome
MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)
This is a randomized prospective study into metabolic adverse events during different types of initial antiretroviral therapy in HIV-1-infected men.
- Trial name
- NCT00122226
- Testing
- Lopinavir/ritonavir + zidovudine + lamivudine, Lopinavir/ritonavir + nevirapine
- Where
- 13 sites in Finland, Netherlands and 2 more
- Volunteers
- 50 people
- Sponsor
- Amsterdam UMC, location VUmc
Hiv, Tuberculosis
Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
This is a drug interaction study in HIV negative, TB-monoinfected participants coming to the end of continuation phase of TB therapy, to study the pharmacokinetic changes to dolutegravir when administered with standard, medium…
- Trial name
- DoRIS (NCT04166474)
- Testing
- Dolutegravir
- Where
- 2 sites in South Africa, Uganda
- Volunteers
- 36 people
- Sponsor
- Helen Reynolds
Human Immunodeficiency Virus, Acquired Immune Deficiency Syndrome Virus
Prospective Evaluation of HIV Patients Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis
Human immunodeficiency virus (HIV) infection is a major global health issue with up to 40 million people infected worldwide. Due to highly active antiretroviral therapy, mortality related to acquired immunodeficiency syndrome…
- Conditions
- Human Immunodeficiency Virus, Acquired Immune Deficiency Syndrome Virus, Liver Diseases, Liver Cirrhosis
- Trial name
- Prospec-HIV (NCT02542020)
- Where
- Brazil
- Volunteers
- 2,000 people
- Sponsor
- Oswaldo Cruz Foundation
Acquired Immunodeficiency Syndrome
Chinese Network of Pediatric Antiretroviral Therapy
This is an observational cohort in pediatric HIV patients in China. Children who receive antiretroviral drugs will be recruited in this study. The main objectives are as follows: 1.
- Trial name
- CN-PART (NCT01210924)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- National Center for AIDS/STD Control and Prevention, China CDC
HIV Infections
A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease
To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who are HIV-infected and either symptomatic or have a CD4 cell count < 400 cells/mm3 and to monitor adverse effects of AZT.
- Trial name
- NCT00000662
- Testing
- Zidovudine
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Latent Tuberculosis Infection
Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons
The purpose of this study is to evaluate whether isoniazid can safely (and further) reduce the risk of tuberculosis in HIV infected people receiving HAART.
- Conditions
- Tuberculosis, Latent Tuberculosis Infection, HIV Infections
- Trial name
- HAART-IPT (NCT00463086)
- Testing
- isoniazid
- Where
- South Africa
- Volunteers
- 1,368 people
- Sponsor
- University of Cape Town
HIV Infections
A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)
Part 1A: To find the dose of zidovudine (AZT) that causes less than a 50 percent drop in HIV-1 p24 antigen levels in patients with AIDS and advanced AIDS related complex (ARC); to determine the pharmacokinetics (blood levels) of…
- Trial name
- NCT00000659
- Testing
- CD4 Antigens, Zidovudine
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis, HIV/AIDS
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
Background: Standard treatment for the hepatitis C virus (HCV) is a combination of the drugs peg-IFN and ribavirin. However, this treatment is not very effective in people with a serious type of HCV (HCV genotype 1) and also in…
- Trial name
- NCT01443923
- Testing
- Boceprevir, Peg-Interferon-alfa 2B, Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, HIV Infections
Tushirikiane HIV-self Testing Intervention With Urban Refugee Youth in Kampala, Uganda
HIV is the leading cause of death for adolescents and young people (AYP) in sub-Saharan Africa (SSA). Uganda hosts 1.3 million refugees/displaced persons, and more than 80,000 live in Kampala, most in slums, yet little is known…
- Conditions
- HIV/AIDS, HIV Infections, Knowledge, Attitudes, Practice
- Trial name
- Tushirikiane (NCT04504097)
- Testing
- m-Health, HIV self-testing
- Where
- Canada
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Infection, Human Immunodeficiency Virus
DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)
The purpose of this study is to determine if there is an interaction in healthy subjects taking BMS-663068 with Darunavir/Ritonavir and/or Etravirine.
- Trial name
- NCT02063360
- Testing
- BMS-663068, Darunavir (DRV), Ritonavir (RTV)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
The purpose of this study is to assess the safety and immunogenicity of M72/AS01E vaccination in virally suppressed, antiretroviral-treated participants with human immunodeficiency virus infection (HIV).
- Trial name
- MESA-TB (NCT04556981)
- Testing
- M72/AS01E Mycobacterium tuberculosis vaccine
- Where
- 6 sites in South Africa
- Volunteers
- 402 people
- Sponsor
- Gates Medical Research Institute
Hiv, Adherence, Medication
Making ART Work Among Brazilian Youth
This study seeks to develop and pilot test a theory-based, integrated technology and counseling intervention to improve ART adherence among sexual and gender minority (SGM) young people living with HIV (ages 18-24) in Rio de…
- Trial name
- NCT06056037
- Testing
- Experimental: Making ART Work, Standard of Care
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Brown University
Tuberculosis, Tuberculosis (TB)
Questioning the Epidemiology of Asymptomatic TB
Tuberculosis (TB) remains one of the world's leading causes of morbidity and mortality. Current TB control strategies focus largely on the binary paradigm of TB, which tackle Mtb infection and the symptomatic stages of the…
- Conditions
- Tuberculosis, Tuberculosis (TB), HIV, HIV (Human Immunodeficiency Virus)
- Trial name
- TB QUEST (NCT07312266)
- Where
- Mozambique
- Volunteers
- 6,770 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
HIV, HIV/AIDS
Reducing Proviral HIV DNA With Interferon-a
The purpose of this study is to determine if treatment with pegylated interferon alpha 2b (peg-IFN-α2b) will reduce the amount of integrated HIV DNA in peripheral blood cells and tissues of individuals with chronic HIV infection…
- Trial name
- BEAT-HIV (NCT02227277)
- Testing
- Peg-IFN-α2b
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- The Wistar Institute
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00551330
- Testing
- Vicriviroc
- Volunteers
- 111 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.